SCHEMBL99535

SCHEMBL99535

Cc1c(Cl)cccc1C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.64
MEN1 O00255 2/20 0.64
MAPT P10636 2/20 0.64
KMT2A Q03164 2/20 0.64
USP2 O75604 1/20 0.64
MT-CO2 P00403 1/20 0.64
LMNA P02545 1/20 0.64
TTR P02766 1/20 0.64
PLA2G1B P04054 1/20 0.64
CYP1A2 P05177 1/20 0.64
PGR P06401 1/20 0.64
CYP3A4 P08684 1/20 0.64
HTR1A P08908 1/20 0.64
ADRA2A P08913 1/20 0.64
ADORA3 P0DMS8 1/20 0.64
AR P10275 1/20 0.64
CYP2C9 P11712 1/20 0.64
HTR2A P28223 1/20 0.64
CYP2C19 P33261 1/20 0.64
ADRA1A P35348 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29656832 1.00 HPGD (0.64) HPGDMEN1MAPTKMT2AUSP2
Hydrochloric Acid SCHEMBL15352266 0.98 HPGD (0.62) HPGDMEN1MAPTKMT2AUSP2
SCHEMBL11080512 0.84 MAPT (0.51) HPGDMEN1MAPTKMT2AUSP2
Benzene SCHEMBL27265959 0.84 TSHR (0.61) HPGDMEN1MAPTKMT2AUSP2
SCHEMBL756585 0.84 TSHR (0.61) HPGDMEN1MAPTKMT2AUSP2
SCHEMBL27703149 0.84 TSHR (0.61) HPGDMEN1MAPTKMT2AUSP2
SCHEMBL4631526 0.83 MAPT (0.51) HPGDMEN1MAPTKMT2AUSP2
SCHEMBL108670 0.83 ALDH1A1 (0.52) HPGDMEN1MAPTKMT2AUSP2
SCHEMBL706359 0.83 MAPT (0.50) HPGDMEN1MAPTKMT2AUSP2
SCHEMBL4450233 0.83 MAPT (0.50) HPGDMEN1MAPTKMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118164940-A Preparation method of phthalide 江苏盈科工程设计研究有限公司 2024-06-11 CN claimed
CN-112876403-B Preparation method of apremilast impurity 成都摩尔生物医药有限公司 2022-10-21 CN claimed
CN-112876403-A Preparation method of apremilast impurity 成都摩尔生物医药有限公司 2021-06-01 CN claimed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 EP claimed
CN-106946685-B Preparation method of 2-methyl-3-methoxybenzoic acid and intermediate thereof 江苏联化科技有限公司 2020-06-23 CN claimed
EP-3551633-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2019-10-16 EP claimed
WO-2018108230-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2018-06-21 WO claimed
CN-106946685-A The preparation method of 2- methyl -3- methoxy benzoic acids and its intermediate 江苏联化科技有限公司 2017-07-14 CN claimed
US-8569195-B2 Internal and external donor compounds for olefin polymerization catalysts II BASF CORPORATION (US) 2013-10-29 US claimed
EP-2539375-A2 INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS II BASF Corporation (US) 2013-01-02 EP claimed
WO-2011106480-A2 INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS II BASF CORPORATION (US) 2011-09-01 WO claimed
US-20110207901-A1 INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS II BASF CATALYSTS LLC (US) 2011-08-25 US claimed
EP-1601642-A4 BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX RHEOGENE INC (US) 2007-04-11 EP claimed
EP-1601642-A2 BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX RheoGene, Inc. (US) 2005-12-07 EP claimed
EP-0884096-B1 Semipermeable encapsulated membranes with improved acid and base stability process for their manufacture and their use KOCH MEMBRANE SYSTEMS INC (US) 2005-09-14 EP claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
WO-2004078924-A2 BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX RHEOGENE, INC. (US) 2004-09-16 WO claimed
US-20260144881-A1 HPK1 TARGETING COMPOUNDS AND USES THEREOF ARVINAS OPERATIONS, INC. (US) 2026-05-28 US disclosed
US-4038396-A ANTIPYRETICS, ANALGESICS MERCK & CO., INC. (US) 1977-07-26 US disclosed
US-4034007-A Process for the production of halogenated aromatic carboxylic acids TENNECO CHEMICALS, INC. (US) 1977-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144881-A1 HPK1 TARGETING COMPOUNDS AND USES THEREOF SGK1, PBK, SGK3 HPGD 2936/4885MEN1 4196/4885MAPT 3413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.